Loading
Latest filing published 14 Jun 2021 for Eledon Pharmaceuticals, Inc., €73k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Paul Sean Little, listed as finance chief, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Sientra, Inc. and Eledon Pharmaceuticals, Inc. We count 8 filings; the first trade dates from 8 August 2018 and the latest from 11 June 2021.
On the open market, the record shows 2 purchases worth €162k and 1 sale worth €17k. The net balance comes to €145k on the buying side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 5 share grants. In 2021 alone, the filings show 1 purchase and 1 sale.
The newest entry dates from 14 June 2021: an open-market purchase of €73k, in Eledon Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
1 of 1 declaration